Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang on Lilly's FIPNET Strategies In China: An Interview With PharmAsia News

Eli Lilly, which launched its GLP-1 agonist Byetta (exenatide) in China in 2009, recently expanded its fully integrated pharmaceutical network (FIPNET) strategy by announcing that it would build up a diabetes-focused research center in Shanghai. Following the announcement, Tony Zhang, PhD, Lilly's global external R&D-Asia VP, sat down with PharmAsia News' Shanghai bureau along the sidelines of the BioPartnering China conference to talk about Lilly's evolving R&D strategy in Asia.